ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AHB-121

A development code.

Its studies are mostly in Hepatitis B, Chronic, led by Ausper Biopharma.

Furthest: phase 1, since Oct 14, 20261 company-led study, 1 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ausper Biopharma11 open or runningphase 1since Oct 14, 2026Oct 14, 2026Apr 30, 2027phase 1 · NCT07884864

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2026First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT07884864 · 110 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Hepatitis B, ChronicNCT07884864

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07884864Hepatitis B, Chronic · China1Not yet recruitingApr 30, 2027110

How it is read

Names in the registry

  • “AHB-121”, 1 entry

Codes read as this program: AHB121.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.